Two Dozen-Plus Biotechs Went Public This Year—With More In The Works
In this week’s edition of InnovationRx, the bumper crop of biotech IPOs, Isomorphic’s reported $40 billion valuation fundraise, and the impact of drugmakers’ gifts to doctors.
<p>In this week’s edition of InnovationRx, the bumper crop of biotech IPOs, Isomorphic’s reported $40 billion valuation fundraise, and the impact of drugmakers’ gifts to doctors.</p>